Press Releases

Shanghai, China, August 23, 2021 – WuXi Biologics (“WuXi Bio”) (2269.HK), a global company with leading open-access biologics technology platforms, today announced that industry veteran Ming Tu has joined the company as Executive Vice President and Co-Chief Financial Officer (Co-CFO), reporting to CFO and Executive Vice President Christine Lu-Wong. In this role, Mr. Tu will lead all aspects of WuXi Biologics’ financial strategy, performance, reporting and business planning, as well as functional support, such as treasury, tax, controllership and audit operations. He will also serve on the company’s Executive Council.
 
Dr. Chris Chen, CEO of WuXi Biologics, commented, “With our company experiencing rapid growth worldwide, Ming is joining at the right time to ensure that our operations continue to serve our partners effectively. His 24 years of financial leadership and management roles in a premier global conglomerate will contribute to WuXi Biologics further development as a leading biologics technology provider. Ming is the ideal executive to strengthen our finance function given his extensive financial management, global operations, and strategic planning experience in multinational organizations across the healthcare, services and manufacturing industries.”
 
Mr. Tu’s role at Wuxi Biologics builds on a diverse career in senior financial and operational positions spanning several industries, including healthcare, energy, material science and financial services. He has served as CFO of Home Credit China, one of the largest consumer finance companies in China, since August 2019. Previously, Ming spent 24 years at General Electric (GE), where he served as CFO of GE China, CFO of GE Healthcare China, General Manager (GM) of Global Operations Asia, GM of Global Business Development at GE Energy, and GM of Global Business Development at GE Plastics, serving business units in China, the United States, Japan, and other global locations.
 
Mr. Tu holds a bachelor’s degree from Fudan University. He also attended Wake Forest University and the University of Akron, and obtained an MBA degree in Finance and a Master of Science degree in Information Systems Management. He is a graduate of GE’s Executive Financial Leadership Program and a certified Six Sigma black belt.

About WuXi Biologics

WuXi Biologics (stock code: 2269.HK), a Hong Kong-listed company, is a leading global open-access biologics technology platform offering end-to-end solutions to empower organizations to discover, develop, and manufacture biologics from concept to commercial manufacturing. The company’s history and achievements demonstrate its commitment to providing a truly ONE-stop service offering and strong value proposition to its global clients.

The company is currently conducting on behalf of its clients and partners (as of June 30, 2021) a total of 408 integrated projects, including 212 in pre-clinical development stage; 160 in early-phase (phase I and II) clinical development; 32 in late-phase (phase III) development; and 4 in commercial manufacturing. With a total estimated capacity of exceeding 430,000 liters for biopharmaceutical production planned after 2024 in China, Ireland, the U.S., Germany, and Singapore, WuXi Biologics will provide its biomanufacturing partners with a robust and premier-quality global supply chain network.

WuXi Biologics views Environmental, Social, and Governance (ESG) responsibilities as an integral component of its ethos and business strategy and aims to become a global ESG leader in biologics manufacturing. We use next-generation clean biomanufacturing technologies and utilize cleaner energy sources. We have also established an ESG committee led by the CEO to increase efficiency while advancing commitment to sustainability. For more information about WuXi Biologics, please visit: www.wuxibiologics.com.

Contacts

Media
PR@wuxibiologics.com

Investors
IR@wuxibiologics.com